Loading
A phase 1/2 trial of A2B530 in pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer, run by A2 Biotherapeutics Inc., active and no longer recruiting.
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression is a phase 1/2 interventional study registered as NCT05736731 by A2 Biotherapeutics Inc., with 160 participants enrolled, started 2023-04-28 and due to reach its primary completion in 2026-12. Interventions recorded: A2B530.
Shares A2 Biotherapeutics, Tempus AI, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares A2 Biotherapeutics, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.